🏛️ Verified NIH Record • Updated 2026-07-28
LMN-201 for Prevention of C. Difficile Infection Recurrence (NCT05330182)
A Phase 2, Randomized, Double-blind, Placebo-controlled Study of LMN-201 for Prevention of C. Difficile Infection Recurrence
🔵 Active, Not Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic Sponsor: Lumen Bioscience, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a multisite study to evaluate the safety, tolerability, and efficacy of LMN-201 in participants recently diagnosed with CDI who are scheduled to receive or are receiving SOC antibiotic therapy against C. difficile.
Who can join: Review the eligibility criteria below.
Location: Kaiser Permanente — Escondido, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (15 Sites)
- Kaiser Permanente — Escondido, California
- Gastroenterology Center of Connecticut — Hamden, Connecticut
- University of South Florida — Tampa, Florida
- Metro Infectious Disease Consultants, LLC — Burr Ridge, Illinois
- Baptist Health Research — Lexington, Kentucky
- Henry Ford Health System — Detroit, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Mayo Clinic - Rochester — Rochester, Minnesota
- Weill Cornell Medicine — New York, New York
- IMA Clinical Research — Mount Airy, North Carolina
- MD Anderson Cancer Center — Houston, Texas
- Clinical Alliance for Infectious Diseases - Infectious Diseases, LLC — Annandale, Virginia
- University of Virginia School of Medicine — Charlottesville, Virginia
- Kaiser Permanente-Mid Atlantic — Springfield, Virginia
- UW Health University Hospital — Madison, Wisconsin
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clostridioides Difficile Infection
- Evaluation of GeoHAI Implementation — Columbus, Ohio
- Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy — Milwaukee, Wisconsin
- Lifestyle and Recurrent Clostridioides Difficile Infection (CDI) — Ann Arbor, Michigan
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) — Charlottesville, Virginia
- Secondary Prevention of Clostridioides Difficile Using Vancomycin — Montreal, Quebec
Explore by condition: All Clostridioides Difficile Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.